National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
NCI Drug Dictionary
Page Options
Print This Page
More NCI Dictionaries
Dictionary of Cancer Terms

Glossary of Statistical Terms

NCI Dictionary of Genetics Terms

Terminology Resources
Quit Smoking Today
Search for
# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All

vascular disrupting agent CYT997
An orally bioavailable small-molecule with tubulin-inhibiting, vascular-disrupting, and potential antineoplastic activities. Vascular disrupting agent (VDA) CYT997 inhibits tubulin polymerization in tumor blood vessel endothelial cells and tumor cells, blocking the formation of the mitotic spindle and leading to cell cycle arrest at the G2/M phase; this may result in disruption of the tumor vasculature and tumor blood flow, and tumor cell death. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

Code name:CYT997



Previous:Vanceril, vandetanib, Vantin, Vaqta, varenicline
Next:Vasomax, vatalanib, VCL-CB01 vaccine, Vectibix, vector-peptide conjugated paclitaxel

A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov